TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04701034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Intravenous Immunoglobulins, (Privigen (R), CLS Behring)
Description: infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Tablets
Description: 5 mg before ET and 10 mg after ET until gestational week 8+0

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Human Albumin Solution
Description: Infusion: Initial infusion rate of 0.3 ml/kg BW/hr in about 30 min. If well-tolerated, the infusion rate may gradually be increased to 4.8 ml/kg BW/hr. During the infusion, health care personnel are present to secure immediate action in case of serious AR. Blood pressure and pulse is monitored before, during and after the treatment. In case of anaphylaxis, the treatment is discontinued and the participant is excluded. The hospital ward possess adrenaline 0.1 % solutions ready in case of anaphylaxis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 1 tablet before ET and 2 tablets after ET until gestational week 8+0
Study: NCT04977037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Anodal tDCS will be placed over the primary motor cortex and delivered at 2mA for 20 minutes. Immediately after stimulation ceases, participants will continue with unilateral repetitive arm and finger exercises for 60 minutes. Exercise difficulty will gradually be increased and adjusted per participant's tolerance.
Study: NCT06061705

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Biopsy
Description: Following the start of immunotherapy, an ENT surgeon will perform a cervico-facial tumor biopsy between D30 and D180. This will only be carried out if the tumour tissue is externalized and therefore accessible, and if the biopsy can be performed under local anaesthetic without any constraints for the patient (pain, risk of bleeding).~It consists of a superficial sampling of the externalized tumour lesion under local anaesthetic (xylocaine spray 5%, or xylocaine injectable 1%).~Biopsy of cervico-facial lesions under local anaesthetic is a commonly performed procedure. The main risk of this procedure is bleeding, which is very rare.~The biopsy will not be performed if the surgeon considers that the risk of bleeding is too great. Given the externalized nature of the lesion, biopsy does not entail any risk of tumour dissemination (possible for deep biopsies).~* Four 10-mL blood samples from two heparinized tubes~* Four 5-mL unstimulated saliva samples: non-invasive examination.
Study: NCT05088031

Intervention type: DEVICE
Intervention: shock waves therapy
Description: Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)

Intervention type: DEVICE
Intervention: shock waves therapy
Description: Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)

Intervention type: DEVICE
Intervention: shock waves therapy
Description: Group (A): 20 patients would undergo shock waves plus traditional physical therapy. One thousand shock waves (7 times per sec) were applied at 2.5 Hz at low energy flux densities of 0.01-0.16 mJ/mm2 using a 17 mm head 2-Group (B): 20 patients would undergo intermittent mechanical traction plus conventional physical therapy. Participants would undergo 30 minutes of mechanical traction (with 10-second pull and 5-second rest)
Study: NCT04676815

Intervention type: PROCEDURE
Intervention: NBI and interventional bronchoscopy
Description: NBI used to enhance the contrast between the mucosal surface and underlying blood vessels
Study: NCT04615845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram-DC-PC
Description: Patients will receive 3 times every 2 weeks injection of Cellgram-DC-PC(Autologous dendritic cell) subcutaneously near the inguinal lymph nodes
Study: NCT05002114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Topical CBD cream - special formulation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Not the drug
Study: NCT05132569

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolebrutininb
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutininb
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Film-coated tablet Route of administration: Oral
Study: NCT05270928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI346
Description: IBI346 Antibody and IBI346 CAR-T cell injection
Study: NCT05700071

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI without contrast agent
Study: NCT06242067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil
Description: patients received biweekly Trifluridine/tipiracil (30 mg/m2 twice daily; days 1-5), irinotecan (150 mg/m2; day 1) and bevacizumab (5 mg/kg; day 1).
Study: NCT06217016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICCAUT
Description: In this study ,the ICCAUT strategy include intermittent catheter clamping and active urination training. For patients in the ICCAUT group, intermittent catheter clamping will be initiated at 9:00 AM. The catheter will be clamped for 3 h, followed by a 5-minute release, which is one cycle. The next cycle will begin after the cycle was completed. Catheter training is to conclude at 10:00 PM on the first postoperative day, and the catheter is left open during the night. At 6:00 AM on the second postoperative day, another cycle of catheter training will be performed, with the catheter removed at 9:00 AM. During the training period, if the patient experiences a strong urge to urinate before the 3-hour clamping time is over, the clamping can be released in advance for 5 min, allowing the patient to proceed to the next cycle of bladder training. Each time the catheter is released, we will encourage the patients to actively initiate urination to facilitate complete bladder emptying.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Free drainage
Description: For patients in the free draining group, no intervention will be performed on the catheter during this period. The catheter will be removed at 9:00 AM on postoperative day two.
Study: NCT05918822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Commercial Tablet Formulation
Description: Maribavir commercial tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Commercial Tablet Formulation
Description: Maribavir commercial tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Commercial Tablet Formulation
Description: Maribavir commercial tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Commercial Tablet Formulation
Description: Maribavir commercial tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Commercial Tablet Formulation
Description: Maribavir commercial tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Commercial Tablet Formulation
Description: Maribavir commercial tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.
Study: NCT05525767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: All subjects enrolled will receive bevacizumab .Subjects continued to take medication until disease progression, unacceptable toxicity, withdrawal of informed consent, or discontinuation of medication at the discretion of the investigator.
Study: NCT05918822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir Pediatric Powder-for-oral Suspension Formulation
Description: Maribavir pediatric powder-for-oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole tablet.
Study: NCT05562466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QMF149
Description: QMF149 75/40 μg o.d via Breezhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Budesonide 200 μg o.d via Breezhaler
Study: NCT06077019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol and Fluticasone Furoate
Description: Participants inhale 25 µg vilanterol + fluticasone furoate daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol and Mometasone Furoate
Description: Participants inhale 125 µg indacaterol + mometasone furoate daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants inhale placebo daily
Study: NCT04665661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training
Description: Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity aerobic training
Description: Women will perform treadmill-based aerobic exercise for three days a week, at 70%-85% of MHR for 30 minutes and perceived exertion of 14-16, based on the Borg RPE scale. This range39 is considered to represent HIAT. Aerobic training will be preceded by warm-up exercises for 10 minutes and followed by cool-down exercises for 10 minutes, at a perceived exertion of 11.0 (Borg RPE).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait-list control
Description: Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list control
Description: Women in the wait-list control group will be instructed to continue with their usual activities and manage their pain as normal (i.e., with analgesics).
Study: NCT05482854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytical Treatment Interruption (ATI)
Description: Analytical Interruption of Treatment for 24-48 weeks~ART resumption and follow-up for 24 weeks if the participant meets at least one ART resumption criteria
Study: NCT06295419

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task
Description: cerebral palsy and healthy controls will be evaluated dual task conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual task
Description: cerebral palsy and healthy controls will be evaluated dual task conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single task
Description: cerebral palsy and healthy controls will be evaluated single task conditions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single task
Description: cerebral palsy and healthy controls will be evaluated single task conditions
Study: NCT05655637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: There will be one group, and study will be Quasi Experimental Study. Treatment will be given to all 28 participants, 3 sessions in a week for 4 weeks. Pre and Post treat-meant evaluation will be checked by CFQR+14. All patients will be treated with exercise program of Active cycle breathing techniques(ACBT), Pursed lip breathing, Endurance Exercise 20 to 30 min ( walking, cycling) and strength training with Thera-Bands (Bilateral arm raising, Bilateral knee extension). Exercise capacity will be measured with 6MWT. Dyspnea and fatigue will be measured with Borg scale.
Study: NCT06354270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous fluoride toothpaste
Description: Toothpaste containing 0.454 % weight/weight (w/w) SnF2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular fluoride toothpaste (Crest Cavity Protection)
Description: Regular fluoride toothpaste containing 1100 parts per million (ppm) fluoride.
Study: NCT04761094

Intervention type: DEVICE
Intervention: Insulin pump
Description: Treatment with continuous subcutaneous insulin infusion
Study: NCT05187611

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing
Description: Lead placed in the His-Purkinje system in order to achieve QRS shortening.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Lead is placed in a tributary of the coronary sinus.
Study: NCT04371536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate
Description: Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate
Description: Patients receive ferrous sulfate 3 mg/kg elemental iron once daily in liquid formulation.
Study: NCT05370261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine LipoMicel
Description: Berberine LipoMicel® soft-gels. Total dose of 500 mg of berberine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular Berberine hard-gels
Description: Total dose of 500 mg of berberine
Study: NCT05449782

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cocoa flavanol
Description: Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cocoa flavanol
Description: Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cocoa flavanol
Description: Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Cocoa flavanol
Description: Commercially available Cocoa Via Brand capsules containing 1350 mg cocoa flavanols (6 capsules)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Capsules identical to ccocoa flavanol capsules filled with calorically matched brown sugar (6 capsules)
Study: NCT06248086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2802
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2802
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2802
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-20
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-20
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MA-20
Description: IV infusion
Study: NCT04371536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IRONCHILD
Description: Delivery of the intervention at each visit should take 15 minutes or less.~* Baseline visit (Session 1) content will be viewed~* At 1-month follow-up visit, additional (Session 2) content will be viewed~* At 3-month final visit, patients will view final (Session 3) content
Study: NCT06630806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR446523
Description: Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR446523
Description: Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR446523
Description: Pharmaceutical form: Powder for solution for injection; Route of administration: Subcutaneous (SC)
Study: NCT05417542

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: EEG recording during prematurity or around term

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: EEG recording during prematurity or around term

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: EEG recording during prematurity or around term

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG recording during prematurity or around term

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG recording during prematurity or around term

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: NIRS recording during prematurity or around term

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: NIRS recording during prematurity or around term

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: NIRS recording during prematurity or around term

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS
Description: NIRS recording during prematurity or around term

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIRS
Description: NIRS recording during prematurity or around term
Study: NCT05150613

Intervention type: OTHER
Group type: OTHER
Intervention: No Mask
Description: Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.

Intervention type: OTHER
Group type: OTHER
Intervention: No Mask
Description: Participants fulfilling inclusion exclusion criteria will be asked to sign informed consent. Sealed envelope randomization method would determine order of testing (Group A; No mask, Group B; Surgical mask, Group C; N95 mask). For 6MWT, participants will be asked to walk on 30-meter unimpeded walkway as much as possible \& distance at end is recorded along with number of stops during test. For Bruce Protocol, participants will follow standard stage succession with an abrupt increase in speed \& inclination by end of each 3-minute cycle. The participants will be advised to perform test till exhaustion and level achieved will be recorded. The analyzed data will then be used to calculate VO2max and MET scores. Heart rate, SPO2, respiratory rate will be recorded at baseline, after 2 minutes and at test completion. BP will be recorded at baseline and at completion of test, while perceived discomfort scale \& post-exercise exhaustion scale will be assessed upon completion of exercise testing.
Study: NCT06186609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor 200mg per three to four weeks, for one year
Description: PD-1 inhibitor delivered 200mg once before radiotherapy and 200mg every 3-4 weeks after radiotherapy for one year.~Radiotherapy:56-60Gy/28-30 fraction.
Study: NCT05839431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality for Youth Phobias
Description: The intervention will consist of up to 10, 50-minute-long weekly in-person individual sessions of virtual reality-assisted exposure therapy. This intervention also includes psychoeducation about anxiety/phobias and their maintenance, youth strategies for tolerating distress, and parent strategies for reducing accommodation of anxiety.
Study: NCT05841602

Intervention type: OTHER
Intervention: descriptive
Description: This research was conducted to evaluate nursing care from the perspective of hospitalized children during the Covid-19 pandemic process and to determine their feelings during this process.